HeartBeam's ALIGN-ACS Pilot Study Shows Higher Specificity Than Standard ECG for Heart Attack Assessment

HeartBeam's positive ALIGN-ACS pilot study results, showing higher specificity and comparable sensitivity to standard ECGs for acute coronary syndrome, support the company's push toward a pivotal trial and potential FDA clearance for heart attack assessment, which could expand its market beyond arrhythmia detection.

Houston Metrowire Staff
••Healthcare
HeartBeam's ALIGN-ACS Pilot Study Shows Higher Specificity Than Standard ECG for Heart Attack Assessment

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac monitoring and detection, reported positive results from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment. The findings, presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego, suggest the company's portable, cable-free electrocardiogram (ECG) technology could offer a more specific alternative to standard 12-lead ECGs in assessing acute coronary syndrome (ACS), a condition that includes heart attacks and unstable angina.

The study enrolled 132 adults and compared HeartBeam's 3D ECG technology with standard 12-lead ECGs. HeartBeam demonstrated higher specificity than conventional ECGs (81.8% versus 71.4%) and comparable sensitivity (60.2% versus 63.0%). For ST-elevation myocardial infarction (STEMI), a severe type of heart attack, sensitivity was 82.9% for HeartBeam compared with 83.8% for standard ECGs. All participants successfully recorded their own ECGs under clinical supervision without prior training, highlighting the device's ease of use. The study also found greater consistency among cardiologists interpreting HeartBeam recordings compared with standard ECGs, supporting the technology's potential for remote cardiac assessment.

These results matter because heart attacks are a leading cause of death, and rapid, accurate diagnosis is critical. Standard 12-lead ECGs, while widely used, require trained personnel and multiple leads, limiting their use outside clinical settings. HeartBeam's 3D ECG technology, which collects signals from three non-coplanar directions and synthesizes them into a 12-lead ECG, could enable patients to record their own ECGs wherever they are, potentially accelerating diagnosis and treatment. The higher specificity observed in the pilot study suggests HeartBeam may reduce false positives compared with standard ECGs, which could lower unnecessary hospital admissions and associated costs. The comparable sensitivity indicates the technology is unlikely to miss many true ACS cases, though the slightly lower sensitivity warrants further investigation in larger trials.

HeartBeam plans to use the findings to inform a U.S. pivotal study expected to begin in the first quarter of 2027, with the goal of supporting a future Food and Drug Administration (FDA) submission to expand the system's indication beyond arrhythmia assessment to include heart attack assessment. Although HeartBeam's heart attack assessment technology has received FDA Breakthrough Device Designation, the application remains investigational and is not currently FDA-cleared for heart attack assessment. The company's existing FDA clearance for arrhythmia assessment, granted in December 2024, and for its 12-lead ECG synthesis software in December 2025, provide a foundation for the expanded indication. For details on the cleared indications for use, refer to the company's cleared indications.

If the pivotal study confirms these pilot results, HeartBeam could become the first cable-free device capable of collecting ECG signals in 3D and synthesizing them into a 12-lead ECG for heart attack assessment, redefining cardiac care by enabling remote, patient-administered monitoring. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. To view the full press release, visit https://ibn.fm/8QTjB.

MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire, among other services. For more information, visit MissionIR.

Blockchain Registration

QR Code for Blockchain Registration